A Canadian Study of the Effectiveness of Tresiba® (Insulin Degludec) After Switching Basal Insulin in a Population With Type 1 or Type 2 Diabetes Mellitus
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novo Nordisk A/S
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Informed consent will be obtained before any study-related activities. Study-related activities are any data collection from the medical records of the patient
Male or female age greater than or equal to 18 years at the time of insulin degludec initiation
Type 1 diabetes mellitus or insulin-treated type 2 diabetes mellitus patients
Switched to insulin degludec (± prandial insulin) after any basal insulin (± prandial insulin). Switch must have occurred at least 6 months prior to data collection and the patient may or may not be treated with insulin degludec at the time of patient selection
Previously treated with any basal insulin (± prandial insulin) for at least 6 months prior to switching to insulin degludec
At least one documented medical visit in the first 6 months (closest value in 3 to 9 months window) after insulin degludec initiation
Minimum available data at the time of insulin degludec initiation: age, type of diabetes, HbA1c, duration of diabetes, duration and type of insulin treatment, medical follow-up at the study site for at least 1 year, and an estimated glomerular filtration rate (eGFR) value in the last 12 ±6 months (full data period)
You may not be if
Previous participation in this study. Participation is defined as having signed the Informed Consent in this study
Patients treated by continuous subcutaneous insulin infusion or premix insulin in the 6 months prior to receiving Tresiba
Clareo Health | A Canadian Study of the Effectiveness of Tresiba® (Insulin Degludec) After Switching Basal Insulin in a Population With Type 1 or Type 2 Diabetes Mellitus
